ArticleACS pharmacology & translational science2026
Lentiviral-Mediated Expression of a Novel Transforming Growth Factor‑β (TGF-β) Inhibitor Peptibody Therapeutically Mitigates Established Liver Fibrosis by Modulating Inflammation and Inducing Metabolic Reprogramming.
Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic liver diseases are characterized by an excessive wound-healing response that leads to liver fibrosis. Effective antifibrotic therapies capable of reversing established fibrosis remain an unmet clinical need. TGF-β signaling is enhanced in fibrosis. Thus, it has become a promising therapeutic target to assist in the recovery of liver function. Previously, we showed that the TβRII-SE/Fc fusion protein exerts a robust prophylactic effect on liver fibrogenesis. In this work we aimed to evaluate the therapeutic effect of TβRII-SE/Fc in a preclinically relevant in vivo model of chronic wound healing. We evaluated the effect of intrahepatic administration of a lentiviral vector encoding TβRII-SE/Fc in a rat CCl
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.